Stonebrook Private Inc. Buys New Stake in Edwards Lifesciences Co. (NYSE:EW)

Stonebrook Private Inc. bought a new stake in Edwards Lifesciences Co. (NYSE:EW) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 7,559 shares of the medical research company’s stock, valued at approximately $576,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Turtle Creek Wealth Advisors LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth about $34,000. Operose Advisors LLC increased its stake in Edwards Lifesciences by 247.0% in the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 452 shares during the period. SRS Capital Advisors Inc. increased its stake in Edwards Lifesciences by 292.6% in the third quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 474 shares during the period. NBC Securities Inc. bought a new stake in Edwards Lifesciences in the third quarter valued at about $52,000. Finally, ORG Partners LLC bought a new stake in Edwards Lifesciences in the third quarter valued at about $66,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the sale, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the sale, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Robert W.A. Sellers sold 12,210 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $87.00, for a total transaction of $1,062,270.00. Following the sale, the senior vice president now directly owns 13,087 shares of the company’s stock, valued at $1,138,569. The disclosure for this sale can be found here. Over the last three months, insiders have sold 194,004 shares of company stock worth $17,166,254. Corporate insiders own 1.27% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of EW stock opened at $86.43 on Monday. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $96.12. The firm’s 50 day moving average is $90.28 and its 200-day moving average is $78.95. The firm has a market capitalization of $52.02 billion, a price-to-earnings ratio of 37.25, a PEG ratio of 4.28 and a beta of 1.05. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The company had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. Sell-side analysts forecast that Edwards Lifesciences Co. will post 2.76 EPS for the current fiscal year.

Analyst Ratings Changes

EW has been the topic of a number of analyst reports. Morgan Stanley upped their target price on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the company an “overweight” rating in a research note on Thursday, March 21st. Oppenheimer upped their target price on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a research note on Monday, March 18th. Royal Bank of Canada upped their target price on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research note on Monday, April 15th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a research note on Thursday, March 7th. Finally, Evercore ISI lowered their target price on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a research note on Friday. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $92.71.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.